Intellia Therapeutics rises on narrower Q1 loss
Shares of gene-editing firm Intellia Therapeutics NTLA.O rise 3.4% to $7.54
NTLA reports Q1 net loss of $1.10 per share, narrower than the net loss of $1.12 a year ago
Posts Q1 collaboration revenue of $16.63 million, compared with $28.9 million a year ago
Co says it has cash and cash equivalents of $707.1 million as of March 31, with runway expected into H1 2027
Including session's moves, stock down 35.4% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

GOOGL Vs. MSFT: 2 Monster Stocks to Hold for the Next 5 Years

Tradingkey








